Vaccine development company Novavax, headquartered in Gaithersburg, announced Monday that it expanded Phase 3 clinical trials for its COVID-19 vaccine candidate to include adolescents. The trials will include up to 3,000 youths ages 12-17 at up to 75 sites in the U.S., the company said in a press release. “Through the expansion of our PREVENT-19 […]
vaccine candidate
February 19, 2021 |
Altimmune Announces FDA Approval for Phase 1 COVID-19 Vaccine Clinical Trials
Altimmune, Inc. announced Wednesday that it was approved by the FDA to begin Phase 1 clinical trials for AdCOVID, its single-dose nasal spray COVID-19 vaccine candidate. The clinical stage biopharmaceutical company, headquartered in Gaithersburg, expects to begin volunteer enrollment in the trials in the coming week, according to a statement from the company. “We believe […]
January 29, 2021 |
Novavax’s Vaccine Candidate Shows Nearly 90% Efficacy in UK
Novavax, a vaccine development company headquartered in Gaithersburg, says its COVID-19 vaccine candidate showed 89.3% efficacy in UK clinical trials. The UK study enrolled more than 15,000 volunteers, according to a statement from Novavax on Thursday. More details will be released as data comes in, the company said. Phase 2b results in South Africa showed […]
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia